ABUS
Arbutus Biopharma Corporation
Set alert
- YTD
- -12.47%
- 1 year
- -13.02%
- Open
- 4.28
- Prev close
- 4.28
- Mkt cap
- 645.29M
- Vol
- 2.53M
- Avg vol
- 4.88M
- EPS
- 0.79
- P/E
- 5.33
- Div yield
- 0.00%
More statistics
- Low
- 4.14
- High
- 4.30
- Forward P/E
- -30.67
- Beta
- 0.62
- Short ratio
- 5.03
- Inst. own
- 72.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 4.79
- 200-d avg
- 4.52
- 1y target
- 5.46
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 910.13M
- Trailing P/E
- 6.42
- Forward P/E
- -30.67
- PEG ratio
- 0.00
- Price / sales
- 5.53
- Price / book
- 3.87
- EPS (TTM)
- 0.79
- Beta
- 0.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 84.23%
- Revenue (TTM)
- 181.72M
- Revenue growth
- -90.60%
- Free cash flow
- -80.24M
- Total cash
- 92.63M
- Total debt
- 3.63M
- Return on equity
- 89.58%
- Shares outstanding
- 198.11M
- Short % of float
- 14.19%
- 50-day average
- 4.79
- 200-day average
- 4.52
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 16, 2026
Expected Nov 16, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 16, 2026 | Sep 30, 2026 | -0.0232 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.02 | -0.03 | -0.01 | -50.00% |
| May 13, 2026 | Mar 31, 2026 | -0.03 | 0.87 | +0.90 | +3,000.00% |
| Mar 23, 2026 | Dec 31, 2025 | -0.03505 | -0.01 | +0.03 | +71.47% |
| Nov 13, 2025 | Sep 30, 2025 | -0.056 | -0.04 | +0.02 | +28.57% |
| Aug 6, 2025 | Jun 30, 2025 | -0.02 | 0.01 | +0.03 | +150.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | main | Buy | Buy |
| Aug 11, 2025 | Chardan Capital | main | Buy | Buy |
| Mar 28, 2025 | Chardan Capital | main | Buy | Buy |
| Jan 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arbutusbio.com
News
- FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study
- Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- Why Is Arbutus Biopharma Stock Gaining Friday?
- Arbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of Common Shares At Purchase Price Of Between $5.00 And $5.75 Per Share In Cash
- Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate
- Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
- Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate
- Europe Clears First Flu/COVID Combo Shot From Moderna
- QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Your note
Sign in to keep a note on ABUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDROSKI LINDSAY J.D. | Chief Executive Officer | Stock Award(Grant) | Feb 1, 2026 | 28,000 |
| HASTINGS DAVID C | Chief Financial Officer | Stock Award(Grant) | Feb 13, 2025 | 249,824 |
| NAFTZGER J CHRISTOPHER | General Counsel | Stock Award(Grant) | Feb 13, 2025 | 140,544 |
| NGUYEN TUAN | Chief Financial Officer | Stock Award(Grant) | Feb 1, 2026 | 73,500 |
| SIMS KAREN | Officer | Stock Award(Grant) | Feb 13, 2025 | 155,494 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Two Seas Capital Lp | 9.64% | 19,095,583 | 96.81M | Jun 29, 2026 |
| Morgan Stanley | 8.93% | 17,698,305 | 89.73M | Jun 29, 2026 |
| Whitefort Capital Management, LP | 7.97% | 15,794,261 | 80.08M | Jun 29, 2026 |
| Blackrock Inc. | 6.95% | 13,766,071 | 69.79M | Jun 29, 2026 |
| State Street Corporation | 3.97% | 7,869,179 | 39.90M | Jun 29, 2026 |
| Rubric Capital Management LP | 3.80% | 7,532,937 | 38.19M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.54% | 5,034,547 | 25.53M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.03% | 4,020,969 | 20.39M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.82% | 3,610,292 | 18.30M | Jul 30, 2026 |
| Morgan Stanley Insight Fund | 1.38% | 2,728,775 | 13.83M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.91% | 1,795,131 | 9.10M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.88% | 1,743,856 | 8.84M | Jun 29, 2026 |